Immunotherapy before and after surgery for head and neck cancer
Part of Cancer clinical trials.
This study tests whether giving a combination of immunotherapy (camrelizumab) with either an EGFR antibody or chemotherapy before and after surgery can help treat locally advanced head and neck cancer. It aims to see if this approach improves outcomes compared to standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have head and neck squamous cell carcinoma (not nasopharyngeal cancer).
- You are between 18 and 75 years old.
- Your cancer is stage III or IVb (locally advanced) — for some types, stage III.
- You are willing to have surgery as part of the treatment.
- You have not had prior anti-cancer treatment for this cancer.
- Your overall health is good enough to receive immunotherapy, chemo, and radiation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving a combination of two drugs (an immunotherapy drug called a PD-1 inhibitor and a targeted therapy called cetuximab) before surgery to shrink head and neck cancers. The goal is to see if this approach lowers the chance of the cancer coming back after surgery.
This trial tests a combination of an immunotherapy drug (tirelizumab) with two chemotherapy drugs before surgery for head and neck cancer that has spread to lymph nodes. The goal is to shrink the tumor and improve treatment outcomes.
This trial tests whether giving immunotherapy along with chemotherapy before surgery can help treat locally advanced head and neck cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
This trial tests a new immunotherapy drug (adelbelimab) combined with chemotherapy given before surgery, for people with head and neck cancer. The goal is to see if this combination can shrink the tumor and improve the chances of successful surgery.
This trial tests whether giving tislelizumab (an immunotherapy) with chemotherapy before surgery works better than surgery alone for people with head and neck cancer that has not spread to lymph nodes. It's for cancers that can be removed with surgery, and the goal is to see if the pre-surgery treatment improves outcomes.
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy before surgery can help people with advanced head and neck cancer. It aims to see if the combination is more effective than chemotherapy alone.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.